In Bayer v. Watson, the panel throws out Bayer’s patent to its Staxyn erectile dysfunction drug as being obvious, noting that the district court focused too heavily on the commercial availability of the prior art. The panel...more
11/6/2017
/ Appeals ,
Generic Drugs ,
Indefiniteness ,
Innovative Technology ,
Obviousness ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Reversal ,
Software Patents